Innovative Clinical Pathways in Lung Cancer Care for Vulnerable Populations

弱势群体肺癌护理的创新临床途径

基本信息

  • 批准号:
    8461765
  • 负责人:
  • 金额:
    $ 4.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer death in the world and kills three times as many Americans as any other form of cancer. 1, 2 The five-year survival rate for all patients in whom lung cancer is diagnosed is approximately 15 percent, much lower than the 64 percent for colon cancer, 89 percent for breast cancer and 99 percent for prostate cancer.3 For certain vulnerable populations, lung cancer incidence, prevalence and mortality rates are significantly higher when compared to the general population.4 Research has shown that many diseases, including lung cancer, are caused by differences in access to and quality of care.5 Health disparities in lung cancer care are multifactorial and include access to care, cultural differences, communication issues with providers leading to refusal of care, biologic differences, and the systemic and structural impacts of race and class.6 In addition, studies indicate that disparities exist even in an equal access system, and throughout all areas of the cancer spectrum spanning screening, diagnosis, treatments, as well as survivorship and end of life care1-6. Both the Institute of Medicine Report Unequal Treatment, and individual studies show that disparities exist even in equal access systems like Medicare. 7-11 Given the importance of addressing disparities in lung cancer rates across vulnerable populations, the Division of Women's Health at the Brigham and Women's Hospital seeks a small conference grant to support a joint- initiative with the Dana Farber Cancer Institute (DFCI) entitled Innovative Clinical Pathways in Lung Cancer Care for Vulnerable Populations. This is a two-day stakeholder dissemination and implementation conference. The invitation-only conference will be held at Brigham and Women's Hospital in Boston, Massachusetts in the winter of 2012. The goal of the conference is to design innovative pathways along the full spectrum of lung cancer care that address factors contributing to health disparities in vulnerable populations. The full spectrum of lung cancer care will include risk assessment, detection, diagnosis, and treatment of non-small cell lung cancer (NSCLC), the most common type of lung cancer.7 Design of the innovative pathways to NSCLC care will be informed by an examination of the many factors that influence health disparities, including access to care, cultural differences, communication issues,, biologic differences, and the systemic and structural impacts of race and class including poverty and social injustice.8, 9 Conference attendees will also design a pilot study to test the efficacy of the proposed pathways in providing NSCLC care across vulnerable populations. PUBLIC HEALTH RELEVANCE: Program Director/Principal Investigator (Last, First, Middle): Colson, Yolanda Narrative Lung cancer is the leading cause of cancer death in the world and kills three times as many Americans as any other form of cancer. For certain vulnerable populations, lung cancer incidence, prevalence and mortality rates are significantly higher when compared to the general population. This conference brings together stakeholders to design innovative pathways along the full spectrum of lung cancer care to address factors contributing to these health disparities and to design a pilot study to test the efficacy of the proposed pathways.
描述(由申请人提供):肺癌是世界上癌症死亡的主要原因,在美国死亡的人数是任何其他形式癌症的三倍。1,2所有确诊肺癌患者的五年生存率约为15%,远低于结肠癌的64%,乳腺癌的89%和前列腺癌的99%。与一般人群相比,患病率和死亡率明显较高。4研究表明,许多疾病,包括肺癌,5肺癌护理中的健康差异是多因素造成的,包括获得护理的机会、文化差异、与提供者的沟通问题导致拒绝护理、生物差异以及种族和阶级的系统性和结构性影响。研究表明,即使在平等获取系统中,也存在着差距,这种差距贯穿于癌症谱系的所有领域,包括筛查、诊断、治疗以及生存和临终关怀1 -6。医学研究所报告的不平等待遇和个别研究都表明,即使在医疗保险等平等准入制度中也存在差距。7-11鉴于解决弱势群体肺癌发病率差异的重要性,布里格姆妇女医院妇女健康司寻求一笔小额会议赠款,以支持与达纳法伯癌症研究所(DFCI)的一项联合倡议,题为“弱势群体肺癌护理的创新临床途径”。这是为期两天的利益相关者传播和实施会议。仅限受邀者参加的会议将于2012年冬季在马萨诸塞州波士顿的布莱根妇女医院举行。会议的目标是设计沿着全方位肺癌护理的创新途径,解决导致弱势群体健康差异的因素。肺癌治疗的全方位将包括风险评估、检测、诊断和治疗非小细胞肺癌(NSCLC),这是最常见的肺癌类型。7 NSCLC治疗的创新途径的设计将通过检查影响健康差异的许多因素来了解,包括获得治疗的机会、文化差异、沟通问题、生物差异、以及种族和阶级的系统性和结构性影响,包括贫困和社会不公正。8,9与会者还将设计一项试点研究,以测试拟议途径在弱势人群中提供NSCLC护理的有效性。 公共卫生关系:项目主任/主要研究者(最后,第一,中间):Colson,Yolanda叙述肺癌是世界上癌症死亡的主要原因,杀死的美国人是任何其他形式癌症的三倍。对于某些弱势群体,肺癌的发病率、流行率和死亡率与一般人群相比明显更高。本次会议汇集了利益相关者,以设计创新的途径沿着全方位的肺癌护理,以解决这些健康差距的因素,并设计一个试点研究,以测试拟议的途径的疗效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yolonda L Colson其他文献

Yolonda L Colson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yolonda L Colson', 18)}}的其他基金

Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
  • 批准号:
    10677869
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
  • 批准号:
    10442908
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas
超治疗 PTX 支撑可降低软组织肉瘤手术后的局部复发率
  • 批准号:
    10670441
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
Precise tumor targeting with logic CAR circuits
利用逻辑 CAR 电路精确肿瘤靶向
  • 批准号:
    10330301
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
Precise tumor targeting with logic CAR circuits
利用逻辑 CAR 电路精确肿瘤靶向
  • 批准号:
    10490410
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE
用于预防肺部肿瘤复发的超疏水载药支撑
  • 批准号:
    10331020
  • 财政年份:
    2019
  • 资助金额:
    $ 4.8万
  • 项目类别:
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE
用于预防肺肿瘤复发的超疏水载药支撑
  • 批准号:
    10083724
  • 财政年份:
    2019
  • 资助金额:
    $ 4.8万
  • 项目类别:
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA
优化纳米颗粒肿瘤定位和载药治疗间皮瘤
  • 批准号:
    10083718
  • 财政年份:
    2019
  • 资助金额:
    $ 4.8万
  • 项目类别:
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA
用于治疗间皮瘤的纳米颗粒肿瘤定位和载药优化
  • 批准号:
    10330568
  • 财政年份:
    2019
  • 资助金额:
    $ 4.8万
  • 项目类别:
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE
用于预防肺部肿瘤复发的超疏水载药支撑
  • 批准号:
    10553156
  • 财政年份:
    2019
  • 资助金额:
    $ 4.8万
  • 项目类别:

相似国自然基金

Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Research on the use of clinical pathways to build Value-Based Health Care
利用临床路径构建基于价值的医疗保健的研究
  • 批准号:
    23K09616
  • 财政年份:
    2023
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identify, Teach and Treat (IT2): Automating clinical decision pathways for the care of women
识别、教导和治疗 (IT2):自动化临床决策路径以护理女性
  • 批准号:
    10377834
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
Identify, Teach and Treat (IT2): Automating clinical decision pathways for the care of women
识别、教导和治疗 (IT2):自动化临床决策路径以护理女性
  • 批准号:
    10559508
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
MLTC-M Community of Practice in Clinical Context and Pathways (Clinical Community of Practice)
MLTC-M 临床背景和途径实践社区(临床实践社区)
  • 批准号:
    MR/X004562/1
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Research Grant
Prevalence, Incidence, and Predictors of Subclinical and Clinical Vascular and Myocardial Disease: Pathophysiologic Pathways
亚临床和临床血管和心肌疾病的患病率、发病率和预测因子:病理生理学途径
  • 批准号:
    10333816
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
The Practice and Evaluation of LHS using Clinical Pathways and Electronic Medical Records
使用临床路径和电子病历的 LHS 实践和评估
  • 批准号:
    22K10416
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Prevalence, Incidence, and Predictors of Subclinical and Clinical Vascular and Myocardial Disease: Pathophysiologic Pathways
亚临床和临床血管和心肌疾病的患病率、发病率和预测因子:病理生理学途径
  • 批准号:
    10622456
  • 财政年份:
    2022
  • 资助金额:
    $ 4.8万
  • 项目类别:
A Characterization of Clinical Care Pathways in Neurosurgery in the Canadian Context
加拿大神经外科临床护理途径的特点
  • 批准号:
    466773
  • 财政年份:
    2021
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Studentship Programs
Enabling precision management of glaucoma through discovery of underlying biological pathways and clinical prediction tool development
通过发现潜在的生物学途径和开发临床预测工具,实现青光眼的精准管理
  • 批准号:
    MR/T040912/1
  • 财政年份:
    2020
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Fellowship
Revolutionising health service delivery for musculoskeletal disorders through discovery, simplifying prognosis and implementing novel clinical pathways.
通过发现、简化预后和实施新的临床途径,彻底改变肌肉骨骼疾病的卫生服务提供。
  • 批准号:
    nhmrc : GNT1161467
  • 财政年份:
    2019
  • 资助金额:
    $ 4.8万
  • 项目类别:
    Career Development Fellowships
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了